IDEA: Pooled Analysis of Adjuvant Oxaliplatin for 3 vs 6 Mos in Stage III Colon Cancer

June 2-6, 2017; Chicago, Illinois
In this analysis of 6 phase III trials, DFS and neuropathy rates varied with adjuvant oxaliplatin duration among patients based on risk factors and regimen.
Format: Microsoft PowerPoint (.ppt)
File Size: 232 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for advanced HCC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for early HCC and advanced BTC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

Adjuvant nivolumab prolonged DFS in patients with resected EC/GEJC who had received neoadjuvant chemotherapy compared with placebo; from ASCO as reported by Clinical Care Options (CCO)

Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue